United States - English - NLM (National Library of Medicine)

xiromed, llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine tablets is indicated in - short- term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo – controlled comparative studies have been carried out for periods longer than 1 year. - the treatment of pathological hypersecretory conditions. (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine tablets, usp is indicated in: concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; gerd; and erosive esophagitis. ranitidine tablets, usp is contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients (see precautions).

United States - English - NLM (National Library of Medicine)

vensun pharmaceuticals, inc. - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: - blastomycosis, pulmonary and extrapulmonary - histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and - aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin b therapy. specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: - onychomycosis of the toenail, with or without fingernail involvement

Ireland - English - HPRA (Health Products Regulatory Authority)

orpha-devel handels und vertriebs gmbh - argipressin - concentrate for solution for infusion - 40 iu/2 millilitre(s) - vasopressin and analogues; vasopressin

Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - terlipressin acetate - solution for injection - 1mg/8.5 millilitre(s) - vasopressin and analogues; terlipressin

Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - terlipressin acetate - powder and solvent for solution for injection - 1 milligram(s) - vasopressin and analogues; terlipressin

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - argipressin - solution for injection - 20 unit(s)/millilitre - vasopressin and analogues; argipressin

European Union - English - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystic kidney, autosomal dominant - diuretics, - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with ckd stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

European Union - English - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - inappropriate adh syndrome - diuretics, - treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (siadh).,

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - tolvaptan - inappropriate adh syndrome - diuretics, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).